Metabolic side effects of risperidone in early onset schizophrenia;Effets secondaires métaboliques de la rispéridone dans les schizophrénies début précoce

Encephale

Volumn 36, Issue 3, 2010, Pages 242-252

  Goeb, J L ^a,b   Marco, S ^a   Duhamel, A ^c   Kechid, G ^a,b   Bordet, R ^d   Thomas, P ^a   Delion, P ^a,b   Jardri, R ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CNRS   (France)

^c Faculté de Médecine Pôle Recherché   (France)

^d UNIV LILLE   (France)

Author keywords

Adolescence; BMI; Metabolic syndrome; Risperidone; Schizophrenia; Weight

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AFFECTIVE PSYCHOSIS; ARTICLE; BLOOD PRESSURE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; CHILD PSYCHIATRY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRANCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCHOOL CHILD; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL; WAIST CIRCUMFERENCE;

EID: 77953870662     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2009.10.008     Document Type: Article

References (35)

1. D.B. Allison Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry 156 1999 1686 1696
2. D.B. Allison, J.A. Mackell, and D.D. Mcdonnell The impact of weight gain on quality of life among persons with schizophrenia Psychiatr Serv 54 4 2003 565 567
3. M.G. Aman, G. De Smedt, and A. Derivan Risperidone Disruptive Behavior Study G*roup. Double-blind, placebo-controlled study of risperidone for treatment of disruptive behaviors in children with subaverage intelligence Am J Psychiatry 159 2002 1337 1346
4. American Diabetes Association Consensus development conference on antipsychotic drugs and obesity and diabetes J Clin Psychiatry 65 2004 267 272
5. ANAES. Prise en charge de l'obésité de l'enfant et de l'adolescent. 2003.
6. J. Cheng-Shannon, J.J. Mcgough, and C. Pataki Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 14 3 2004 372 394
7. C.U. Corell New-onset dyslipidemia in antipsychotic-naive youngsters treated with atypical antipsychotics Biol Psychiatry 57 Suppl. 8 2005 36
8. C.U. Correll Body composition changes associated with second-generation antipsychotics Biol Psychiatry 57 Suppl. 8 2005 36
9. C.U. Correll Recognizing and monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents Child Adolesc Psychiatric Clin N Am 15 2006 177 206
10. C. Fleischhaker, P. Heiser, and K. Hennighausen Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents J Neural Transm 114 2 2007 273 280
11. D. Gothelf, B. Falk, and P. Singer A. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine Am J Psychiatry 159 2002 1055 1057
12. J.A. Hellings, J.R. Zarcone, and K. Crandall Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 11 2001 229 238
13. R. Jardri, B. Lucas, and C. Delmaire An 11 year-old boy with drug resistant schizophrenia treated with temporo-parietal rTMS Mol Psychiatry 12 4 2007 320
14. Kechid G., Goeb J.-L., Lemaître V., et al. Obésité infantile: aspects cliniques, psychopathologiques et thérapeutiques. Paris: EMC (Elsevier Masson SAS, Paris), Psychiatrie/Pédopsychiatrie, 37-201-A-25, 2009.
15. D.L. Kelly, R.R. Conley, and R.C. Love Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 8 1998 151 159
16. J.P. Lindenmayer Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics Am J Psychiatry 160 2003 290 296
17. A. Martin, and S. L'Ecuyer Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study Eur Child Adolesc Psychiatry 11 3 2002 129 133
18. A. Martin, J. Landau, and P. Leebens Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 10 2000 259 268
19. J.W. Newcomer Metabolic risk during antipsychotic treatment Clin Ther 26 12 2004 1936 1946
20. M. Olfson, S.C. Marcus, and B. Druss National trends in the use of psychotropic medications by children J Am Acad Child Adolesc Psychiatry 41 2002 514 521 (Pubitemid 38338129)
21. M. Onis, C. Garza, and A.W. Onyango Comite de nutrition de la Société Franaise de pédiatrie Arch Ped 16 2009 47 53
22. E.A. Papadopulos, B. Tate Guelzow, and C. Wong A review of the growing evidence base for pediatric psychopharmacology Child Adolesc Psychiatr Clin N Am 13 4 2004 817 855
23. J. Puig-Antich, and W. Chambers The schedule for affective disorders and schizophrenia for school-age children (Kiddie-Sads) 1978 State Psychiatry Institute New York
24. G. Ratzoni, D. Gothelf, and A. Brand-Gothelf Weight gain associated with olanzapine and risperidone in adolescents patients: a comparative prospective study J Am Acad Child Adolesc Psychiatry 41 3 2002 337 343
25. Research Units On Pediatric Psychopharmacology Autism Network Risperidone in children with autism and serious behavioral problems N Engl J Med 347 2002 314 321
26. D.J. Safer A comparison of risperidone-induced weight gain across the age span J Clin Psychopharmacol 24 4 2004 429 436
27. L. Sikich, R.M. Hamer, and R.A. Bashford A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial Neuropsychopharmacology 29 1 2004 133 145
28. R. Snyder, A. Turgay, and M. Aman Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs J Am Acad Child Adolesc Psychiatry 41 2002 1026 1036
29. J.A. Staller, M.J. Wade, and M. Baker Current prescribing patterns in outpatient child and adolescent practice in Central New York. J Child Adolesc Psychopharmacol 15 1 2005 57 61
30. K.A. Stigler, M.N. Potenza, and D.J. Posey Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management Pediatric Drugs 6 1 2004 33 44
31. P. Toren, N. Laor, and A. Weizman Use of atypical neuroleptics in child and adolescent psychiatry J Clin Psychiatry 59 1998 644 656
32. W.V.R. Vieweg, A.B. Sood, and A. Pandurangi Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? Acta Psychiatr Scand 111 2005 177 184
33. R. Weiss, J. Dziura, and T.S. Burgert Obesity and the metabolic syndrome in children and adolescents N Engl J Med 350 23 2004 2362 2374
34. G. Zalsman, E. Carmon, and A. Martin Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study J Child Adolesc Psychopharmacol 13 2003 319 327
35. J.M. Zito, D.J. Safer, and S. Dosreis Psychotropic practice patterns for youth: a 10-year perspective Arch Pediatr Adolesc Med 157 1 2003 17 25